BACKGROUND: The significance of epidermal growth factor receptor (EGFR) expression in advanced cutaneous squamous cell carcinoma (SCC) of the head and neck remains poorly understood. METHODS: We performed a retrospective review of patients with advanced-stage (stage III or stage IV) cutaneous SCC of the head and neck (n = 56). RESULTS: The majority of patients (91%) had stage III disease, with 54% having regional metastasis and 9% with distant metastasis. Two-year survival was 64% and the 5-year survival was 56%. EGFR was found to be overexpressed in 56% of primary tumors and 58% of regional metastatic disease. Overall survival did not correlate with EGFR (p = .47) expression in primary lesions, nor was it associated with an increase in regional (p = .74) or distant metastasis (p = .56). Furthermore, there was no correlation between clinicopathologic characteristics and EGFR expression CONCLUSIONS: These data do not suggest upregulation of EGFR is associated with poor survival or aggressive disease.
BACKGROUND: The significance of epidermal growth factor receptor (EGFR) expression in advanced cutaneous squamous cell carcinoma (SCC) of the head and neck remains poorly understood. METHODS: We performed a retrospective review of patients with advanced-stage (stage III or stage IV) cutaneous SCC of the head and neck (n = 56). RESULTS: The majority of patients (91%) had stage III disease, with 54% having regional metastasis and 9% with distant metastasis. Two-year survival was 64% and the 5-year survival was 56%. EGFR was found to be overexpressed in 56% of primary tumors and 58% of regional metastatic disease. Overall survival did not correlate with EGFR (p = .47) expression in primary lesions, nor was it associated with an increase in regional (p = .74) or distant metastasis (p = .56). Furthermore, there was no correlation between clinicopathologic characteristics and EGFR expression CONCLUSIONS: These data do not suggest upregulation of EGFR is associated with poor survival or aggressive disease.
Authors: Gianmauro Numico; Elvio Grazioso Russi; Ida Colantonio; Rosa Anna Lantermo; Nicola Silvestris; Raffaele Vitiello; Alberto Comino; Mario Abrate; Carla Zavattero; Antonella Melano; Marco Merlano Journal: Anticancer Res Date: 2010-02 Impact factor: 2.480
Authors: Anjali K Gupta; W Gillies McKenna; Charles N Weber; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Mitchell Machtay; David I Rosenthal; Vincent J Bakanauskas; George J Cerniglia; Eric J Bernhard; Randal S Weber; Ruth J Muschel Journal: Clin Cancer Res Date: 2002-03 Impact factor: 12.531
Authors: Ezra E W Cohen; Fred Rosen; Walter M Stadler; Wendy Recant; Kerstin Stenson; Dezheng Huo; Everett E Vokes Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: K Kian Ang; Brian A Berkey; Xiaoyu Tu; Hua-Zhong Zhang; Ruth Katz; Elizabeth H Hammond; Karen K Fu; Luka Milas Journal: Cancer Res Date: 2002-12-15 Impact factor: 12.701
Authors: Kristine E Day; Lauren N Beck; C Hope Heath; Conway C Huang; Kurt R Zinn; Eben L Rosenthal Journal: Cancer Biol Ther Date: 2013-01-08 Impact factor: 4.742
Authors: Larissa Sweeny; Andrew Prince; Neel Patel; Lindsay S Moore; Eben L Rosenthal; Brian B Hughley; Jason M Warram Journal: Laryngoscope Date: 2016-08-31 Impact factor: 3.325
Authors: C Hope Heath; Nicholas L Deep; Lisle Nabell; William R Carroll; Renee Desmond; Lisa Clemons; Sharon Spencer; J Scott Magnuson; Eben L Rosenthal Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-22 Impact factor: 7.038
Authors: Ying-Gui Yang; Young Wha Koh; Ita Novita Sari; Nayoung Jun; Sanghyun Lee; Lan Thi Hanh Phi; Kwang Seock Kim; Yoseph Toni Wijaya; Sang Hun Lee; Moo-Jun Baek; Dongjun Jeong; Hyog Young Kwon Journal: Int J Cancer Date: 2018-12-08 Impact factor: 7.396